PE20181487A1 - Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj) - Google Patents

Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)

Info

Publication number
PE20181487A1
PE20181487A1 PE2018001129A PE2018001129A PE20181487A1 PE 20181487 A1 PE20181487 A1 PE 20181487A1 PE 2018001129 A PE2018001129 A PE 2018001129A PE 2018001129 A PE2018001129 A PE 2018001129A PE 20181487 A1 PE20181487 A1 PE 20181487A1
Authority
PE
Peru
Prior art keywords
apj
heteroarylhydroxypirimidinones
receptor agonists
compounds
apelin receptor
Prior art date
Application number
PE2018001129A
Other languages
English (en)
Spanish (es)
Inventor
Michael C Myers
R Michael Lawrence
Donna M Bilder
Wei Meng
Zulan Pi
Robert Paul Brigance
Heather Finlay
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20181487A1 publication Critical patent/PE20181487A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/04Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D417/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cardiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Pyridine Compounds (AREA)
PE2018001129A 2015-12-16 2016-12-15 Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj) PE20181487A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201562267997P 2015-12-16 2015-12-16

Publications (1)

Publication Number Publication Date
PE20181487A1 true PE20181487A1 (es) 2018-09-18

Family

ID=57708840

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018001129A PE20181487A1 (es) 2015-12-16 2016-12-15 Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)

Country Status (21)

Country Link
US (1) US10669261B2 (enExample)
EP (1) EP3390400B1 (enExample)
JP (1) JP6948322B2 (enExample)
KR (1) KR102742744B1 (enExample)
CN (1) CN108602813B (enExample)
AR (1) AR107061A1 (enExample)
AU (1) AU2016372048B2 (enExample)
BR (1) BR112018012112A2 (enExample)
CA (1) CA3008630A1 (enExample)
CL (1) CL2018001621A1 (enExample)
CO (1) CO2018007221A2 (enExample)
EA (1) EA036736B1 (enExample)
ES (1) ES2854733T3 (enExample)
HK (1) HK1255163A1 (enExample)
IL (1) IL259947B (enExample)
MX (1) MX380669B (enExample)
PE (1) PE20181487A1 (enExample)
SG (1) SG11201804674UA (enExample)
TW (1) TW201725203A (enExample)
UY (1) UY37026A (enExample)
WO (1) WO2017106396A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL3303330T3 (pl) 2015-06-03 2019-10-31 Bristol Myers Squibb Co Agoniści 4 - hydroksy - 3 - ( heteroarylo ) pirydyno - 2 - onowi receptora apj do stosowania w leczeniu zaburzeń sercowo-naczyniowych
UY36949A (es) 2015-10-14 2017-04-28 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware 2,4-dihidroxi-nicotinamidas como agonistas de apj
EA037257B1 (ru) 2015-12-04 2021-02-26 Бристол-Маерс Сквибб Компани Новые агонисты рецептора апелина и способы применения
MA55064A (fr) 2015-12-16 2021-09-29 Loxo Oncology Inc Composés utilisés comme inhibiteurs de kinase
CN109195963B (zh) 2016-03-24 2021-04-23 百时美施贵宝公司 作为apj激动剂的6-羟基-4-氧代-1,4-二氢嘧啶-5-甲酰胺
EP3452466B1 (en) 2016-05-03 2020-08-12 Amgen Inc. Heterocyclic triazole compounds as agonists of the apj receptor
US10889565B2 (en) 2016-06-14 2021-01-12 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1H)-ones as APJ receptor agonists
CN109311821B (zh) 2016-06-14 2022-10-14 百时美施贵宝公司 作为apj激动剂的6-羟基-5-(苯基/杂芳基磺酰基)嘧啶-4(1h)-酮
CN110072850B (zh) 2016-10-14 2023-07-21 百时美施贵宝公司 3-磺酰基-5-氨基吡啶-2,4-二醇apj激动剂
US11020395B2 (en) 2016-11-16 2021-06-01 Amgen Inc. Cycloalkyl substituted triazole compounds as agonists of the APJ receptor
US10736883B2 (en) 2016-11-16 2020-08-11 Amgen Inc. Triazole furan compounds as agonists of the APJ receptor
US10689367B2 (en) 2016-11-16 2020-06-23 Amgen Inc. Triazole pyridyl compounds as agonists of the APJ receptor
WO2018093579A1 (en) 2016-11-16 2018-05-24 Amgen Inc. Triazole phenyl compounds as agonists of the apj receptor
US11046680B1 (en) 2016-11-16 2021-06-29 Amgen Inc. Heteroaryl-substituted triazoles as APJ receptor agonists
US11191762B2 (en) 2016-11-16 2021-12-07 Amgen Inc. Alkyl substituted triazole compounds as agonists of the APJ Receptor
US11807624B2 (en) 2018-05-01 2023-11-07 Amgen Inc. Substituted pyrimidinones as agonists of the APJ receptor

Family Cites Families (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2263639A (en) 1992-01-28 1993-08-04 Merck & Co Inc Substituted pyrimidinones as neurotensin antagonists
US6174998B1 (en) 1996-03-12 2001-01-16 Roche Diagnostics Gmbh C-nucleoside derivatives and their use in the detection of nucleic acids
JPH08311041A (ja) 1995-03-16 1996-11-26 Takeda Chem Ind Ltd 複素環化合物およびその剤
KR100579765B1 (ko) 1996-07-01 2006-12-28 닥터 레디스 레보러터리즈 리미티드 신규헤테로고리형화합물의제조방법,이를함유하는약제조성물및당뇨병및이와관련된질병의치료에있어서그의용도
US6369067B1 (en) 1997-10-27 2002-04-09 Dr. Reddy's Research Foundation Monocyclic compounds and their use in medicine: process for their preparation and pharmaceutical compositions containing them
HU229479B1 (en) * 2000-02-16 2014-01-28 Glaxo Group Ltd Pyrimidine-4-one derivatives
CA2416248A1 (en) 2000-07-18 2002-01-24 Neurogen Corporation 5-substituted 2-aryl-4-pyrimidinones
WO2002081454A1 (en) 2001-04-09 2002-10-17 Dr. Reddy's Laboratories Ltd. Derivatives of aryl acids, their use in medicine, process for their preparation and pharmaceutical compositions containing them
WO2003094839A2 (en) 2002-05-09 2003-11-20 Cytokinetics, Inc. Pyrimidinone compounds, compositions and methods
WO2003099211A2 (en) 2002-05-23 2003-12-04 Merck & Co., Inc. Mitotic kinesin inhibitors
US20070167621A1 (en) 2003-04-03 2007-07-19 Pharmacia Corporation Substituted pyrimidinones
EP1620428A1 (en) 2003-04-23 2006-02-01 Pharmacia & Upjohn Company LLC Substituted pyrimidinones and pyrimidinthiones as crf antagonists
WO2005026148A1 (en) 2003-09-08 2005-03-24 Takeda San Diego, Inc. Dipeptidyl peptidase inhibitors
US20050197327A1 (en) 2003-11-03 2005-09-08 Gustave Bergnes Compounds, compositions, and methods
US7625912B2 (en) 2003-12-19 2009-12-01 Merck & Co. Inc Mitotic kinesin inhibitors
JP4517349B2 (ja) 2004-07-28 2010-08-04 宇部興産株式会社 ピリミジン−4−オン化合物の製造方法
DE102005025315A1 (de) 2005-06-02 2006-12-14 Merck Patent Gmbh Ionische Flüssigkeiten mit niedriger Viskosität
WO2007037543A1 (ja) 2005-09-29 2007-04-05 Banyu Pharmaceutical Co., Ltd. ビアリールアミド誘導体
EP1963329B1 (en) 2005-11-30 2013-01-23 Vertex Pharmaceuticals Incorporated Inhibitors of c-met and uses thereof
US8367845B2 (en) 2006-04-21 2013-02-05 The Trustees Of Boston University Ionic viscoelastics and viscoelastic salts
WO2008052861A2 (de) 2006-10-10 2008-05-08 Proionic Production Of Ionic Substances Gmbh & Co Keg Verfahren zur herstellung von 1,3 -hetero-aromatischen carbonaten
ES2527722T3 (es) 2006-10-10 2015-01-28 Proionic Gmbh & Co Kg Método para reaccionar 2-carboxilatos 1,3-heteroaromáticos con agua
JP2010519204A (ja) 2007-02-16 2010-06-03 アムジエン・インコーポレーテツド 窒素含有複素環ケトン類およびそれらのc−Met阻害薬としての使用
WO2009152902A2 (en) 2008-05-28 2009-12-23 Merck Patent Gmbh, Ionic liquids
DE102008031480A1 (de) 2008-07-03 2010-01-07 Merck Patent Gmbh Salze enthaltend ein Pyrimidincarbonsäure-Derivat
WO2010072696A2 (de) 2008-12-22 2010-07-01 Basf Se Mischungen hydrophober und hydrophiler ionischer flüssigkeiten und ihre verwendung in flüssigkeitsringverdichtern
TW201100411A (en) 2009-05-21 2011-01-01 Chlorion Pharma Inc Pyrimidines as novel therapeutic agents
US9212130B2 (en) 2010-08-10 2015-12-15 Shionogi & Co., Ltd. Heterocyclic derivative and pharmaceutical composition comprising the same
CN103597646A (zh) 2011-05-31 2014-02-19 默克专利股份有限公司 电解质组合物
TWI567084B (zh) 2011-05-31 2017-01-21 麥克專利有限公司 含有氫-三氰-硼酸根陰離子之化合物
CN102903954B (zh) 2011-07-25 2015-06-03 微宏动力系统(湖州)有限公司 含有离子液体电解质的锂离子二次电池
DE102012006896A1 (de) 2012-04-05 2013-10-10 Merck Patent Gmbh Silikate mit organischen Kationen
EP3409666A3 (en) 2012-06-07 2019-01-02 Georgia State University Research Foundation, Inc. Seca inhibitors and methods of making and using thereof
CA2885272A1 (en) * 2012-09-21 2014-03-27 Sanofi Benzoimidazole-carboxylic acid amide derivatives as apj receptor modulators
WO2014056844A1 (en) 2012-10-10 2014-04-17 Basf Se Ionic liquids based on oxalic acid mono esters
DE102012021452A1 (de) 2012-10-31 2014-04-30 Merck Patent Gmbh Salze mit Trihydroperfluoralkoxybutansulfonat- oder Trihydroperfluoralkoxypropansulfonat-Anion
US20150291596A1 (en) 2012-11-16 2015-10-15 Biocryst Pharmaceuticals, Inc. Antiviral azasugar-containing nucleosides
WO2014207100A1 (en) 2013-06-27 2014-12-31 Basf Se A process for coating paper with cellulose using a solution containing cellulose
DE102013016324A1 (de) 2013-10-04 2015-04-09 Merck Patent Gmbh Perfluoralkylfluor- oder Perfluoralkylchlorgermanate
CA2930343C (en) 2013-11-29 2021-06-08 Proionic Gmbh Method for curing an adhesive using microwave irradiation
KR101550846B1 (ko) 2014-01-29 2015-09-07 한국과학기술연구원 단일공정을 이용한 탄소소재의 다원소 도핑방법 및 그 용도
KR101531023B1 (ko) 2014-05-27 2015-06-23 한국과학기술연구원 열분해 가스 도핑에 의한 고강도 고전도성 탄소나노튜브섬유의 제조방법 및 이에 따라 제조된 탄소나노튜브섬유
US10570128B2 (en) * 2014-05-28 2020-02-25 Sanford Burnham Prebys Medical Discovery Institute Agonists of the apelin receptor and methods of use thereof
MX387055B (es) * 2014-06-06 2025-03-19 Res Triangle Inst Agonistas del receptor de apelina (apj) y usos de los mismos.
WO2016074757A1 (de) 2014-11-11 2016-05-19 Merck Patent Gmbh Verfahren zur herstellung von mono- und bis(perfluoralkyl)fluorophosphatsalzen und deren säuren
PL3303330T3 (pl) * 2015-06-03 2019-10-31 Bristol Myers Squibb Co Agoniści 4 - hydroksy - 3 - ( heteroarylo ) pirydyno - 2 - onowi receptora apj do stosowania w leczeniu zaburzeń sercowo-naczyniowych
UY36949A (es) 2015-10-14 2017-04-28 Bristol-Myers Squibb Company Una Corporación Del Estado De Delaware 2,4-dihidroxi-nicotinamidas como agonistas de apj
EA037257B1 (ru) 2015-12-04 2021-02-26 Бристол-Маерс Сквибб Компани Новые агонисты рецептора апелина и способы применения
CN109195963B (zh) 2016-03-24 2021-04-23 百时美施贵宝公司 作为apj激动剂的6-羟基-4-氧代-1,4-二氢嘧啶-5-甲酰胺
US10889565B2 (en) 2016-06-14 2021-01-12 Bristol-Myers Squibb Company 4-hydroxy-3-sulfonylpyridin-2(1H)-ones as APJ receptor agonists
CN109311821B (zh) 2016-06-14 2022-10-14 百时美施贵宝公司 作为apj激动剂的6-羟基-5-(苯基/杂芳基磺酰基)嘧啶-4(1h)-酮
CN110072850B (zh) 2016-10-14 2023-07-21 百时美施贵宝公司 3-磺酰基-5-氨基吡啶-2,4-二醇apj激动剂

Also Published As

Publication number Publication date
US20180362508A1 (en) 2018-12-20
CL2018001621A1 (es) 2018-08-03
CA3008630A1 (en) 2017-06-22
IL259947A (en) 2018-07-31
IL259947B (en) 2020-10-29
AR107061A1 (es) 2018-03-14
EA201891336A1 (ru) 2019-01-31
WO2017106396A1 (en) 2017-06-22
JP2018538304A (ja) 2018-12-27
CO2018007221A2 (es) 2018-07-19
JP6948322B2 (ja) 2021-10-13
UY37026A (es) 2017-06-30
ES2854733T3 (es) 2021-09-22
US10669261B2 (en) 2020-06-02
EA036736B1 (ru) 2020-12-14
EP3390400B1 (en) 2021-01-20
AU2016372048A1 (en) 2018-08-02
MX380669B (es) 2025-03-12
CN108602813B (zh) 2021-10-29
KR20180095577A (ko) 2018-08-27
HK1255163A1 (zh) 2019-08-09
AU2016372048B2 (en) 2021-02-04
SG11201804674UA (en) 2018-06-28
BR112018012112A2 (pt) 2018-12-04
CN108602813A (zh) 2018-09-28
KR102742744B1 (ko) 2024-12-12
EP3390400A1 (en) 2018-10-24
TW201725203A (zh) 2017-07-16
MX2018007155A (es) 2018-08-15

Similar Documents

Publication Publication Date Title
PE20181487A1 (es) Heteroarilhidroxipirimidinonas como agonistas del receptor de apelina (apj)
PE20181269A1 (es) Agonistas del receptor de apelina y metodos de uso
PE20161405A1 (es) Analogos de cortistatina y sintesis y usos de los mismos
MX2015017865A (es) Compuestos de pirimidinodiona contra estados cardiacos.
PE20180483A1 (es) Oxiesteroles y metodos de uso de los mismos
AR090760A1 (es) Compuestos de benzotiazol y su uso contra el virus de hiv
PE20120034A1 (es) Compuestos derivados de n-fenilpirimidin-2-amina
CO2018004344A2 (es) Derivados de heterociclos bicíclicos condensados como agentes de control de plagas
PE20142461A1 (es) Moduladores del receptor de estrogeno y sus usos
PE20180506A1 (es) Agonistas de receptor de apelina (apj) de 4-hidroxi-3-(heteroaril) piridin-2-ona como para uso en el tratamiento de trastornos cardiovasculares
CO2017002714A2 (es) Ácido 4-(3-fluoro-3-(2-(5,6,7,8-tetrahidro-1,8-naftiridin-2-il)etil)pirrolidin-1-il)-3-(3-(2-metoxietoxi)fenil)butanoico, o una sal del mismo
PE20181197A1 (es) 2,4-dihidroxi-nicotinamidas como agonistas del receptor de apelina (apj)
PE20160664A1 (es) Compuestos heteroaromaticos y su uso como ligandos d1 de dopamina
PE20141827A1 (es) Inhibidores de proteinas quinasas
AR113688A1 (es) Proceso para la preparación de compuestos de piridiminio ópticamente activo
PE20170664A1 (es) Agonistas del receptor de apelina(apj) y usos de los mismos
PE20170325A1 (es) Compuestos y composiciones como agonistas del receptor tipo toll
AR092827A1 (es) Compuestos de n-(tetrazol-5-il)- y n-(triazol-5-il)arilcarboxamida sustituidos y su uso como herbicidas
AR096339A1 (es) Agonistas del receptor de somatostatina subtipo 4 (sstr4)
DOP2016000242A (es) Uso de compuestos heterocíclicos para controlar nematodos
PE20141828A1 (es) 6-alquinilo piridinas como mimeticos smac
ECSP18024565A (es) Benzamidas sustituidas con isoxazolinas y análalogos como insecticidas
PE20171511A1 (es) Compuestos de piperidina urea 4-metilsulfonil-sustituidos para el tratamiento de miocardiopatia dilatada (mcd)
PE20160589A1 (es) Heteroaril-ciclohexil-tetraazabenzo[e]azulenos como antagonistas de los receptores de vasopresina v1a
PE20161444A1 (es) 1,2-ciclopentanos sustituidos como antagonistas del receptor de orexina